Showing results (51-60 of 263) with videos related to
Sort By:
Pageof 27
Seminars in Oncology|April 1, 1992
A phase I study of daily oral teniposide for 20 daysE F Smit, T A Splinter, T C KokNederlands Tijdschrift Voor Geneeskunde|October 21, 1989
[Dysphagia due to 'mediastinal carcinomatosis', a late sequela of breast carcinoma]A M Huisman, T A Splinter, M van BlankensteinScandinavian Journal of Haematology|January 1, 1978
CLL and diffuse histiocytic lymphoma in one patient: clonal proliferation of two different B cellsT A Splinter, B V Noorloos, P Van HeerdeCancer Chemotherapy and Pharmacology|January 1, 1987
Problems of pharmacokinetic studies on alpha-difluoromethylornithine in miceJ C Romijn, C F Verkoelen, T A SplinterSeminars in Urologic Oncology|March 21, 1998
Immunological approaches for the treatment of prostate cancerS F Slovin, W K Kelly, H I ScherJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcomeH W Herr, D F Bajorin, H I ScherThe Netherlands Journal of Medicine|December 18, 2001
Arterial occlusive events during chemotherapy for germ cell cancerA H Vos, T A Splinter, C van der HeulJournal of Cancer Research and Clinical Oncology|January 1, 1989
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot studyT A Splinter, H Obertop, T C Kok, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 1996
5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study GroupT C Kok, A van der Gaast, T A SplinterSeminars in Oncology|December 1, 1992
What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposideT A Splinter, A van der Gaast, T C KokPageof 27